All News
🟢 Opus Genetics is trading 6% up in pre-market with no clear company-specific catalyst
Opus Genetics is trading 5.67% higher at $4.04 in pre-market on October 23, with no clear company-specific catalyst identified. - Compared with the October 22...
Stock Extends Winning Streak to 9 Days; Nisa Investment Advisors Increases Stake
Cognizant Technology Solutions Corp. marked a nine-day winning streak. The company added approximately $6.8 billion to its market value. Its stock surged 24.5%...
🟢 Tech ETF (CHPS) is trading 1.82% up in pre-market as chipmakers stage selective rebound
CHPS is trading at $76.23, up 1.82%, amid signs of a selective semiconductor rebound. - After October 22’s tech selloff, pre-market sentiment was mixed:...
🟢 Shift4 Payments is trading 7.1% up in pre-market
Shift4 Payments is trading at $43.00, up 7.05% in pre-market, with no clear catalyst identified for the move. - After the October 22 close, Shift4 announced...
🟢 DSL is trading 3.38% up in pre-market; catalyst remains unclear
DSL is trading at $10.10, up 3.38% in pre-market, with the catalyst unclear. - No company-specific announcement explaining the October 23 pre-market rise was...
🟢 Cerenome is trading 5.7% up in pre-market — catalyst remains unclear
Cerenome is trading at $1.85, up +5.71%, with no confirmed catalyst for the pre-market move. - No fresh company announcement dated October 23, 2026, was...
🔴 Natural Gas ETF (BOIL) is trading 3.05% down in pre-market as mild forecasts curb heating demand
BOIL is trading at $17.53 (-3.05%) as mild U.S. weather forecasts into early November curb expected heating demand and weigh on natural gas futures. -...
🟢 ARTY is trading 1.56% up in pre-market
ARTY is trading at $69.94, up 1.56% pre-market, with no new ARTY-specific announcement or clear catalyst identified for the move. - The prior-session...
🟢 Immix Biopharma is trading 8% up in pre-market with no clear company-specific catalyst
Immix Biopharma is trading at $9.00, up +7.78%, before the October 23, 2026 open, with no clear company-specific announcement tied to the move. - The latest...
Rithm Capital's third quarter 2026 revenue of $1.76B beat estimates while book value expanded
Rithm Capital reported third quarter 2026 results that exceeded top-line expectations, supported by scaling its alternative asset management platform and...
🔴 BioLineRx is trading 6.7% down in pre-market
BioLineRx is trading 6.7% down at $1.95 in pre-market, with no clear company-specific announcement identified as the reason. - The company’s...
Balchem Corporation reports record third quarter 2026 sales of $291M with growth in all segments
Balchem Corporation achieved record consolidated net sales and earnings for the third quarter of 2026, supported by organic growth across its entire portfolio....
Xencor's Kidney Cancer Drug Gets Its Biggest Test Yet — Can Early Data Justify a Stock That Has Already Doubled?
Shares surged +8.4% to $28.00 as Xencor's most important clinical catalyst arrived: early-stage trial results for its experimental kidney cancer drug, a...
🟢 Tech ETF (HUMN) is trading 13.53% up in pre-market; no verified overnight catalyst
HUMN is trading at $29.99 (+13.53%) in pre-market, with no verified overnight catalyst explaining the sharp rise. - Available sector news points the other...
🟢 BIO-key International is trading 14% up in pre-market after Gulf-region government institution selected PortalGuard IAM
BIO-key International is trading at $3.12, up 13.98%, after a Gulf-region government institution selected its PortalGuard IAM platform and biometric...
🔴 Mednax is trading 4% down in pre-market
Mednax is trading 4.3% lower at $28.27, compared with its October 22 close of $29.55. - The provided market backdrop is mildly negative but does not show a...
🟢 Xencor is trading 8.4% up in pre-market ahead of scheduled XmAb819 Phase 1 results
Xencor is trading at $28.00, up 8.36%, ahead of scheduled XmAb819 Phase 1 updates, though available coverage does not directly link the pre-market move to...
🔴 Verizon Communications is trading 4.1% down in pre-market after report SpaceX seeks U.S. cell-site access
Verizon Communications is trading 4.1% down at $43.37 after a report that SpaceX is seeking access to at least 80,000 U.S. cell sites. - Reuters reported...
🔴 GE HealthCare is trading 4.03% down in pre-market with no clear company-specific catalyst
GE HealthCare is trading at $68.50, down 4.03%, before the open on October 23; no clear company-specific catalyst has surfaced. - The October 22 close was...
🟢 Blaize Holdings is trading 9.35% up in pre-market with no clear catalyst identified
Blaize Holdings is trading at $0.27, up 9.35%, with no clear fresh catalyst identified for the October 23 pre-market gain. - The move is opposite the supplied...